Scholar Rock launches $200 million at-the-market stock offering program

Scholar Rock Holding Corporation (SRRK) has launched an at-the-market (ATM) offering to sell up to $200 million of common stock, leveraging strong liquidity despite a recent net loss of $315.69 million. This capital raise comes as the company faces a delay in the commercial launch of its lead drug candidate, apitegromab, due to an FDA Official Action Indicated (OAI) status at a key manufacturing facility. Analyst reactions are mixed, with Truist Securities lowering its price target to $44 while BofA Securities initiated coverage with a Buy rating and a $53 target, citing optimism for apitegromab's potential in spinal muscular atrophy.

Analysis

Scholar Rock Holding Corporation (SRRK) has initiated an At-The-Market (ATM) offering to sell up to $200 million of common stock, representing a notable capital raise against its $2.89 billion market capitalization and a $315.69 million net loss over the last twelve months. This move is supported by the company's strong liquidity profile, with current assets exceeding short-term obligations by over six times, as per InvestingPro data.

A significant operational headwind is the FDA's Official Action Indicated (OAI) status for a Catalent facility, owned by Novo Nordisk, critical for apitegromab production. This regulatory action has directly caused a delay in the commercial launch of SRRK's lead drug candidate, apitegromab, impacting the company's projected timelines and contributing to a "moderately negative" general sentiment.

Analyst reactions to these developments are mixed, reflecting uncertainty. Truist Securities adjusted its price target downwards from $54 to $44 while maintaining a Buy rating, acknowledging the delay. Conversely, BofA Securities initiated coverage with a Buy rating and a $53 price target, underscoring optimism regarding apitegromab's potential in spinal muscular atrophy (SMA).

Key Decisions for Investors

• Investors should closely monitor Scholar Rock's progress in resolving the FDA's Official Action Indicated (OAI) status and any updated timelines for apitegromab's commercial launch.
• Consider the potential dilutive effects of the $200 million ATM offering against the company's enhanced capital position and strong existing liquidity.
• Evaluate the long-term therapeutic potential of apitegromab in SMA, weighing it against the immediate operational risks and the mixed analyst sentiment.